Megan Lancaster

Has grant

Assistant Professor

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

A Regulatory-First Framework to Reveal Noncoding Cardiomyopathy

Open Date: 2026-07-01

Close Date: 2028-06-30

Grant: Open

A high-throughput, multimodal strategy to improve variant classification

Open Date: 2025-01-03

Close Date: 2029-12-31

Articles (8)

Year:

2026

Year:

2026

Year:

2025

Variants in the familial hypercholesterolemia gene LDLR —the most important genetic driver of cardiovascular disease—can raise circulating low-density lipoprotein (LDL) cholesterol concentrations and increase the risk of premature atherosclerosis. Definitive classifications are lacking for nearly half of clinically encountered LDLR missense variants, limiting interventions that reduce disease burden. We tested the impact of ~17,000 (nearly all possible) LDLR coding variants on both LDLR cell-surface abundance and LDL uptake, yielding sequence–function maps that recapitulate known biochemistry, offer functional insights, and provide evidence for interpreting clinical variants. Functional scores correlated with hyperlipidemia phenotypes in prospective human cohorts and augmented polygenic scores to improve risk inference, highlighting the potential of this resource to accelerate familial hypercholesterolemia diagnosis and improve patient outcomes.

Year:

2025

Year:

2024

Year:

2024

Background Drug-induced QT interval prolongation raises the risk of fatal arrhythmia and is a central issue in safety pharmacology. Yet individual QT drug response is highly variable, and risk stratification remains a challenge. We hypothesized that genetic factors underlying the baseline QT influence this variation in QT drug response. Methods A cohort of 990 healthy subjects was prospectively challenged with a single 80 mg oral sotalol dose. Exclusion criteria included abnormal ECG, cardiac disease, and QT-prolonging drug use. ECGs were obtained at baseline and 3 hours post-dose. QT response was defined as absolute change in Fridericia heart-rate corrected QT (ΔQTc). Plasma sotalol was measured 3 hours post-dose. Subjects were genotyped on the MEGA array. Principal component analysis of genotypes was used to define genetic ancestry. A polygenic risk score (PRS) for the baseline QTc comprised of 465,399 common variants was calculated from assayed and imputed genotypes. The difference in PRS between subjects with high QT response (ΔQTc≥60 ms) and those with ΔQTc<60ms was assessed by Mann Whitney test. A multivariable regression model was used to assess the association between PRS and ΔQTc after covariate adjustment. Results: Of the 990 subjects, 978 (99%) passed genomic quality control and were included in analysis. 62% were female (n=607), with median age 23 (interquartile range (IQR) 21-33). The median ΔQTc 3 hours post-sotalol was 21 ms (IQR 12-30). Ten subjects (1%) had ΔQTc≥60 ms, and their PRS was significantly higher compared to those with ΔQTc<60 ms (P=0.0082). In the regression model, PRS was positively associated with ΔQTc (P=0.0002). Conclusion Common genetic variants associated with the baseline QT also capture part of the repolarization response to sotalol. This adds to the emerging concept that the genetic architecture of a trait can predict drug response.

Year:

2024

Background We identified a novel SCN5A variant, E171Q, in a neonate with very frequent ectopy and reduced ejection fraction which normalized after arrhythmia suppression by flecainide. This clinical picture is consistent with multifocal ectopic Purkinje-related premature contractions (MEPPC). Most previous reports of MEPPC have implicated SCN5A variants such as R222Q that neutralize positive charges in the S4 voltage sensor helix of the channel protein Na V 1.5 and generate a gating pore current. Methods and Results E171 is a highly conserved negatively-charged residue located in the S2 transmembrane helix of Na V 1.5 domain I. E171 is a key component of the Gating Charge Transfer Center, a region thought to be critical for normal movement of the S4 voltage sensor helix. We used heterologous expression, CRISPR-edited induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), and molecular dynamics simulations to demonstrate that E171Q generates a gating pore current, which was suppressed by a low concentration of flecainide (IC50 = 0.71±0.07 µM). R222Q shifts voltage dependence of activation and inactivation in a negative direction but we observed positive shifts with E171Q. E171Q iPSC-CMs demonstrated abnormal spontaneous activity and prolonged action potentials. Molecular dynamics simulations revealed that both R222Q and E171Q proteins generate a water-filled permeation pathway that underlies generation of the gating pore current. Conclusion Previously identified MEPPC-associated variants that create gating pore currents are located in positively-charged residues in the S4 voltage sensor and generate negative shifts in the voltage dependence of activation and inactivation. We demonstrate that neutralizing a negatively charged S2 helix residue in the Gating Charge Transfer Center generates positive shifts but also create a gating pore pathway. These findings implicate the gating pore pathway as the primary functional and structural determinant of MEPPC and widen the spectrum of variants that are associated with gating pore-related disease in voltage-gated ion channels.

Year:

2024

Collaborators (23)

Matthew O'Neill

Brigham and Women's Hospital

UNITED STATES
View details

Simon Georg Pfisterer

University of Helsinki

FINLAND
View details

Eric Smith

University of Michigan

UNITED STATES
View details

Robert Hegele

Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function

Western University

CANADA
View details

Julia Cadrin-Tourigny

Clinical Assistant Professor

Université de Montréal

CANADA
View details

Kenneth Matreyek

Assistant Professor

Case Western Reserve University

UNITED STATES
View details

Mafalda Bourbon

Invited Professor

Faculty of Medicine, University of Lisbon

PORTUGAL
View details

Qianru Wang

Associate Professor (non-tenured)

Shanghai Jiao Tong University

CHINA
View details

Dan M Roden

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Adam Helms

Assistant Professor

University of Michigan

UNITED STATES
View details

Andrew Glazer

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Joe-Elie Salem

Professor of Medicine and Pharmacology

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Melina Claussnitzer

Assistant Professor

Harvard University

UNITED STATES
View details

Nosheen Reza

University of Pennsylvania

UNITED STATES
View details

Christian Funck-Brentano

Emeritus Professor / Delegate Research Integrity Officer

Sorbonne Université

FRANCE
View details

Frederick Roth

Professor and Chair

University of Pittsburgh

UNITED STATES
View details

Kristen Medo

Research Services Professional

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Yuko Wada

-

UNITED STATES
View details

David Samuels

Associate Professor

Vanderbilt University

UNITED STATES
View details

Shubhayan Sanatani

Professor

The University of British Columbia

CANADA
View details

Perry Elliott

University College London

UNITED KINGDOM
View details

Douglas Fowler

Professor

University of Washington

UNITED STATES
View details

Calum MacRae

Professor

Harvard University

UNITED STATES
View details